Foster Dykema Cabot & Co’s Novartis NVS Stock Holding History

Foster Dykema Cabot & Co’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$14K	Buy	+133	New	+$13.5K	﹤0.01%	219

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Foster Dykema Cabot & Co's NVS Position: Q3 2023 in Review

Foster Dykema Cabot & Co opened a new position in Novartis (NVS) in Q3 2023: 133 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #219 among its holdings.

1,223 funds tracked by Wall St. Rank hold NVS as of Q3 2023.

Foster Dykema Cabot & Co held 133 shares of Novartis worth $14K as of Q3 2023.
Novartis was a new Foster Dykema Cabot & Co position in Q3 2023.
Novartis made up ﹤0.01% of Foster Dykema Cabot & Co's portfolio in Q3 2023, its #219 holding.
1,223 funds tracked by Wall St. Rank held Novartis as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.